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Abstract 19 
Influenza A/H2N2 viruses caused a pandemic in 1957 and continued to circulate in 20 
humans until 1968. The antigenic evolution of A/H2N2 viruses over time and the 21 
amino acid substitutions responsible for this antigenic evolution are not known. Here, 22 
the antigenic diversity of a representative set of human A/H2N2 viruses isolated from 23 
1957 until 1968 was characterized. Antigenic change of influenza A/H2N2 viruses 24 
during the 12 years that this virus circulated was modest. Two amino acid 25 
substitutions, T128D and N139K, located in the head domain of the H2 26 
hemagglutinin molecule were identified as important determinants of antigenic 27 
change during A/H2N2 virus evolution. The rate of A/H2N2 virus antigenic evolution 28 
during the twelve-year period after introduction in humans was half of that of A/H3N2 29 
viruses, despite similar rates of genetic change.  30 
 31 
Importance 32 
While influenza A viruses of subtype H2N2 were at the origin of the Asian influenza 33 
pandemic, little is known about the antigenic changes that occurred during the twelve 34 
years of circulation in humans, the role of preexisting immunity and evolutionary 35 
rates of the virus. In this study, the antigenic map derived from hemagglutination 36 
inhibition titers of cell-cultured virus isolates and ferret post-infection sera displayed a 37 
directional evolution of viruses away from earlier isolates. Furthermore, individual 38 
mutations in close proximity to the receptor-binding site of the HA molecule 39 
determined the antigenic reactivity confirming that individual amino acid substitutions 40 
in A/H2N2 viruses can confer major antigenic changes. This study adds to our 41 
understanding of virus evolution with respect to antigenic variability, rates of virus 42 
evolution, and potential escape mutants of A/H2N2. 43 
 44 
Introduction  45 
Influenza A viruses of the H2N2 subtype initiated a pandemic in 1957, causing 46 
morbidity and mortality in humans, an event also known as the ‘Asian flu pandemic’ 47 
(1-3). No surveillance systems were in place in 1957 to accurately detect and record 48 
the A/H2N2 pandemic outbreak scenario. Based on death certificates and 49 
newspaper articles, excess-mortality was found to occur in waves with the highest 50 
number of events between October 1957 and March 1958 in 5-14 year-olds (4). The 51 
A/H2N2 virus originated upon reassortment between a previously circulating 52 
seasonal human A/H1N1 virus and an avian A/H2N2 virus. The latter virus 53 
contributed the hemagglutinin (HA), neuraminidase (NA), and polymerase basic 54 
protein 1 (PB1) gene segments to the pandemic A/H2N2 virus (5-7). This virus 55 
circulated in the human population until it was replaced by an A/H3N2 influenza virus 56 
in 1968. Today, more than 50 years after the last detected A/H2N2 virus infection in 57 
humans, immunity against A/H2N2 viruses is waning. The threat of reintroduction 58 
and spread of H2 viruses in humans remains, because A/H2N2 viruses and other 59 
influenza A viruses with combinations of H2 and varying NA genes continuously 60 
circulate in avian species and incidentally in swine (8-10). Several vaccine 61 
candidates have been developed for pandemic preparedness (11-13) and 62 
prophylactic vaccination of individuals at increased risk has been proposed (14). 63 
The HA glycoprotein of influenza A viruses is the major target for neutralizing 64 
antibodies and continuously undergoes antigenic evolution by acquiring substitutions 65 
to escape antibody-mediated immunity (15). Five antigenic sites in the HA molecule 66 
have been identified to determine antigenic properties of seasonal human influenza 67 
viruses (16-18). In the case of A/H2N2 influenza viruses, six antigenic sites (I-A to I-68 
D and II-A, II-B) in the HA have been recognized to play a major role in antigenic 69 
change (19). These sites structurally correspond to the five sites described for 70 
A/H3N2 influenza viruses (designated A-E). Site II-A is unique for A/H2N2 influenza 71 
viruses, highly conserved and located in the HA stem domain. 72 
After seminal studies have described the structural importance of the HA receptor-73 
binding site (RBS) for antigenic variation (17, 20, 21), recently, it was shown that a 74 
mere seven amino acid positions on HA located immediately adjacent to the receptor 75 
binding site (RBS) largely determined antigenic changes that occurred during 76 
A/H3N2 influenza virus circulation in humans from 1968 to 2003 (22). Similarly, a 77 
study on clade 2.1 A/H5N1 viruses showed that substitutions in close proximity to the 78 
RBS dictated antigenic change of avian A/H5N1 influenza viruses emerging in 79 
poultry (23), and amino acid changes close to the RBS were found to induce 80 
antigenic change in A/H1N1pdm09 viruses (24-26). Substitutions in the headdomain 81 
of the HA molecule have also been demonstrated to determine the antigenic 82 
phenotype of equine and swine influenza A viruses (27, 28). Combined, these 83 
studies demonstrate the importance of RBS-proximal substitutions for antigenic drift 84 
of influenza A viruses. 85 
In this study, the antigenic properties of a representative set of human A/H2N2 virus 86 
isolates spanning the period from 1957 to 1968 were assessed with respect to their 87 
reactivity to ferret post-infection sera in hemagglutination inhibition assays. The 88 
substitutions responsible for major antigenic differences between A/H2N2 influenza 89 
viruses were mapped by site-directed mutagenesis and generation of recombinant 90 
viruses. 91 
 92 
Materials and Methods 93 
Biosafety considerations 94 
All experiments involving A/H2N2 viruses were conducted under biosafety level 95 
(BSL) 3 conditions. Reassortant viruses in the backbone of A/Puerto Rico/8/34 96 
(H1N1) harboring the HA gene of A/H2N2 viruses were used under BSL-2 97 
conditions. 98 
 99 
Ferret antisera 100 
Ferret post-infection antisera were prepared against virus isolates A/Japan/305/1957 101 
(JP/305/57), A/Singapore/1/1957 (SP/1/57), A/Netherlands/K1/1963 (NL/K1/63), 102 
A/England/1/66 (EN/1/66), A/Tokyo/3/67 (TY/3/67), and A/Netherlands/B1/1968 103 
(NL/B1/68). To this end, male ferrets (Mustela putorios furo) were obtained from an 104 
accredited ferret breeder. All animals tested negative for antibodies against H1, H2, 105 
and H3 influenza A viruses, influenza B virus and Aleutian Disease Virus prior to the 106 
start of the experiments. Ferret antisera were prepared by intranasal inoculation of 107 
the animals with the respective virus, and antisera were collected 14 days after 108 
inoculation. Ferret housing and animal experiments were conducted in strict 109 
compliance with European guidelines (EU directive on animal testing 86/609/EEC) 110 
and Dutch legislation (Experiments on Animal Act, 1997). The experimental protocol 111 
was approved by an independent animal experimentation ethical review committee 112 
(‘Stichting Dier Experimenten Commissie Consult’). Animal welfare was monitored 113 
daily and all animal handling was performed under sedation to minimize discomfort.  114 
 115 
Viruses and cells 116 
Eighteen A/H2N2 viruses were used in this study (accession numbers for HA gene in 117 
brackets); A/Netherlands/M1/57 (KM402801), A/Netherlands/M2/57 (KM885170), 118 
A/Singapore/1/57 (CY125894), A/Netherlands/M1/58 (CY077741), 119 
A/Netherlands/N1/59 (CY077904), A/Netherlands/H1/60 (CY077786), 120 
A/Netherlands/67/63 (CY125886), A/Netherlands/K1/1963 (CY077733), 121 
A/England/12/64 (AY209967), A/Sydney/2/64 (KP412320), A/Taiwan/1/1964 122 
(DQ508881), A/Moscow/56/65 (CY031603), A/England/1/66 (KP412318), 123 
A/England/10/67 (AY209980), A/Tokyo/3/67 (AY209987), A/Netherlands/61/68 124 
(KP412319), A/Netherlands/B1/68 (KM402809), A/Netherlands/B2/68 (KM885174). 125 
Human A/H2N2 virus samples from the Netherlands were collected from individuals 126 
with influenza-like symptoms during the years 1957-1968. From these samples, virus 127 
isolates were obtained by culture in tertiary Monkey Kidney cells (tMK) and Madin-128 
Darby Canine Kidney cells (MDCK) for a maximum of five passages without prior 129 
inoculation in embryonated chicken eggs. Complete HA genes of viruses 130 
A/Netherlands/M1/1957 and A/Netherlands/B2/1968 were amplified from low-131 
passaged viruses and cloned in a modified pHW2000 expression plasmid as 132 
described previously (29). Recombinant viruses consisting of the HA gene of 133 
A/H2N2 and the 7 remaining gene segments of A/Puerto Rico/8/34 (A/H1N1) were 134 
generated by reverse genetics (30). Introduction of mutations in the HA gene was 135 
performed using the QuikChange multi-site directed mutagenesis kit (Agilent 136 
Technologies, Amstelveen, The Netherlands) according to manufacturer’s 137 
instructions. The presence or absence of mutations was confirmed by sequence 138 
analysis of the HA gene. Virus stocks were generated by inoculation of MDCK cells 139 
with 293T transfection supernatant. The inoculum was removed after 2 hours and 140 
replaced by MDCK infection medium, consisting of EMEM, 100 IU/ml penicillin, 100 141 
μg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 10 mM Hepes, 142 
non-essential amino acids, and 25 μg/ml TPCK-treated trypsin. Subsequently, cells 143 
were incubated at 37°C and 5% CO2 and virus-containing supernatant was 144 
harvested three days after inoculation. 145 
293T cells were cultured in Dulbecco modified Eagle’s medium (DMEM, Lonza 146 
Benelux, Breda, the Netherlands) supplemented with 10% fetal calf serum (FCS), 147 
100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, 1 mM sodium 148 
pyruvate, and non-essential amino acids (MP Biomedicals). MDCK cells were 149 
cultured in Eagle’s minimal essential medium (EMEM, Lonza) supplemented with 150 
10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml 151 
sodiumbicarbonate (Lonza), 10 mM HEPES (Lonza), and non-essential amino acids 152 
(MP Biomedicals). 153 
 154 
Hemagglutination inhibition assays 155 
HI assays using a panel of post-infection ferret antisera were performed as 156 
described previously (15). Briefly, ferret antisera were treated with receptor 157 
destroying enzyme (Vibrio cholerae neuraminidase) and incubated at 37°C 158 
overnight, followed by inactivation of the enzyme at 56°C for one hour. Twofold serial 159 
dilutions of the antisera, starting at a 1:20 dilution, were mixed with 25 μl PBS 160 
containing four hemagglutinating units of virus and were incubated at 37°C for 30 161 
minutes. Subsequently, 25 μl 1% turkey erythrocytes were added and the mixture 162 
was incubated at 4°C for one hour. HI titers were read and expressed as the 163 
reciprocal value of the highest dilution of the serum that completely inhibited 164 
agglutination of virus and erythrocytes. 165 
 166 
Computational analyses 167 
Amino acid sequences of human A/H2N2 HA1 were aligned and analyzed by 168 
Maximum Likelihood phylogeny using PhyML 3.0 software (31). The sequence of 169 
avian A/H2N2 isolate A/mallard/Netherlands/31/2006 (ACR58563) was used as an 170 
outgroup. 171 
Antigenic maps were constructed as described previously (15). Antigenic 172 
cartography is a method for the quantitative analysis and visualization of HI data. In 173 
an antigenic map, the distance between antiserum point S and antigen point A 174 
corresponds to the difference between the log2 of the maximum titer observed for 175 
antiserum S against any antigen and the log2 of the titer for antiserum S against 176 
antigen A. Each titer in an HI table can be thought of as specifying a target distance 177 
for the points in an antigenic map. Modified multidimensional scaling methods are 178 
used to arrange the antigen and antiserum points in the antigenic map to best satisfy 179 
the target distances as specified by the HI data. The result is a map in which the 180 
distance between the points represents antigenic distance as measured by the HI 181 
assay in which the distances between antigens and antisera are inversely related to 182 
the log2 HI titer. Since antisera are tested against multiple antigens, and antigens 183 
tested against multiple antisera, many measurements can be used to determine the 184 
position of the antigen and antiserum in an antigenic map, thus improving the 185 
resolution of interpreting HI data. 186 
The amino acid positions responsible for major changes in HI patterns were plotted 187 
on the surface of the crystal structure of A/Singapore/1/1957 HA (PDB accession 188 
code 2WR7 (32) using MacPyMOL (The PyMOL Molecular Graphics System, 189 
Version 1.3, Schrödinger, LLC). 190 
Overall rates of evolutionary change (nucleotide substitutions per site per year) were 191 
estimated using the BEAST program version 1.8.1 (33), the uncorrelated log-normal 192 
relaxed molecular clock and the HKY85 substitution model (34). This analysis was 193 
conducted with a time-aware linear Bayesian skyride coalescent tree prior (35) over 194 
the unknown tree space, with relatively uninformative priors on all model parameters 195 
using the GTR+G+I model with no codon positions enforced. Two independent 196 
Bayesian MCMC analyses for HA1 for 50 million states, sampling every 5000 states, 197 
were performed. Convergences and effective sample sizes of the estimates were 198 
checked using Tracer version 1.5 (http://tree.bio.ed.ac.uk/software/tracer/) and the 199 
first 10 % of each chain was discarded as burn-in. Uncertainty in parameter 200 
estimates is reported as values of the 95 % highest posterior density (HPD). 201 
 202 
Results 203 
Genetic and antigenic diversity of A/H2N2 viruses 204 
The genetic variation of human A/H2N2 influenza viruses isolated between 1957 and 205 
1968 was assessed by Maximum Likelihood algorithms in an HA1 amino acid 206 
phylogenetic tree (Figure 1). The tree displays a ladder-like structure indicating 207 
gradual accumulation of mutations over time. A set of 18 human A/H2N2 influenza 208 
virus isolates representative of genetic variation over the 12-year period and that 209 
was available in our laboratory was compiled (highlighted in red color in Figure 1). 210 
HI titers of the set of 18 A/H2N2 viruses and six A/H2N2 ferret post-infection sera 211 
revealed a typical pattern of influenza virus antigenic drift, with high antibody titers of 212 
antisera against homologous and contemporary viruses and lower titers against non-213 
contemporary strains (Table 1). HI titers were processed using antigenic cartography 214 
methods to yield an antigenic map (Figure 2), revealing directional antigenic 215 
progression of later isolates away from early strains over time. Viruses isolated in the 216 
same or subsequent years generally grouped together in the map and thus were 217 
antigenically similar. Exceptions were A/Sydney/2/64 and the latest A/H2N2 viruses. 218 
In this study, the maximum antigenic distance between any pair of wildtype viruses 219 
was 6.4 antigenic units between A/Netherlands/M1/1958 (NL/M1/58) and 220 
A/Netherlands/B2/1968 (NL/B2/68). Viruses isolated in 1964 were antigenically 221 
highly diverse; whereas A/England/12/1964 (EN/12/64) and A/Taiwan1/64 (TW/1/64) 222 
drifted 3.9 units away from NL/M1/57, A/Sydney/2/1964 (SY/2/64) was only 1.6 223 
antigenic units away from NL/M1/57. The three viruses isolated shortly before the 224 
introduction of the first A/H3N2 virus in 1968 (NL/61/68, NL/B1/68, NL/B2/68) were 225 
particularly divergent in the antigenic map with 3.2 antigenic units difference between 226 
NL/61/68 and NL/B2/68. 227 
 228 
Molecular basis of antigenic change in A/H2N2 viruses 229 
The head domain of the HA molecule is the main target of neutralizing antibodies 230 
(17, 36). Previous studies indicated that amino acid substitutions near the RBS and 231 
exposed on the surface of the HA molecule were responsible for major antigenic drift 232 
of influenza A/H3N2, A/H5N1 viruses and influenza B virus (23, 25, 37). Amino acid 233 
changes on positions 100-250 were compared as a coarse outline of the globular 234 
head domain including the RBS area of the H2 HA. A set of 7 amino acid 235 
substitutions (T126E, T128D, R132K, N139K, S154P, A184T, A188T) was 236 
consistently found in later A/H2N2 virus isolates as compared to the earlier strains 237 
and hence could explain the antigenic differences between early and late strains. 238 
Throughout this study, amino acid positions are numbered as suggested by Burke 239 
and Smith (38). Single amino acid substitutions and combinations thereof were 240 
introduced and tested in recombinant viruses harboring the HA gene of NL/M1/57 or 241 
NL/B1/68 in the backbone of A/Puerto Rico/8/34 (A/H1N1). All reverse-genetics 242 
viruses were rescued, with the exception of NL/B1/68 HA K132R mutant virus 243 
despite three independent rescue attempts. 244 
A substitution at position 139 was responsible for substantial antigenic change of 2.9 245 
antigenic units (AU) when tested both in viruses containing HA genes of NL/M1/57 246 
and NL/B1/68 (Figure 3A, B, Table 2). This position is surface exposed and located 247 
on a protruding loop adjacent to the RBS (Figure 3E). All other individual mutations 248 
in NL/M1/57 and NL/B1/68 had an antigenic effect of less than 1.7 AU compared to 249 
the wildtype virus. The effect of N139K in NL/M1/57 increased with the addition of 250 
T128D to 3.6 antigenic units distance from the NL/M1/57 virus carrying the NL/M1/57 251 
wildtype HA (Figure 3C). When the combination of K139N and D128T was tested in 252 
NL/B1/68 HA, only a rather small difference in antigenic effect (1.1 AU) was 253 
measured compared to K139N alone (Figure 3D). Here, a combination of six amino 254 
acid substitutions (E126T, D128T, K139N, S154P, A184T, A188T) was necessary in 255 
order for the virus to be antigenically similar to NL/M1/57 and located 5.4 antigenic 256 
units from NL/B1/68. Each substitution in addition to K139N had a rather small but 257 
incremental effect on the antigenic reactivity of the H2N2 HA. 258 
 259 
Evolutionary rates of A/H2N2 and A/H3N2 260 
Next, the genetic and antigenic change over time after introduction of the new 261 
influenza virus subtype in the human population was investigated (Figure 4). The 262 
rate of evolution of A/H2N2 HA1 was estimated and compared to the rate of HA1 263 
evolution during the first 12 years of A/H3N2 circulation after its introduction in the 264 
human population in 1968, based on phylogenetic trees generated here and by 265 
Smith et al. (15). The average rate of genetic evolution (nucleotide substitutions per 266 
site per year) as estimated in this analysis was 8.47×10-3 for H2N2 and 7.53×10-3 for 267 
H3N2 (Figure 4A). The average rate of antigenic evolution for A/H2N2 from 1957-268 
1968 was 0.4 AUs per year as calculated from the slope of the best-fit regression 269 
line of the distances in the antigenic map (Figure 4B). Using the A/H3N2 dataset 270 
reported by Smith et al. (15) the maximum distance in the antigenic map during the 271 
first 12 years of circulation (1968 - 1979) was 13.3 AUs between isolates 272 
A/Bilthoven/16190/1968 and A/Bangkok/1/1979, resulting in an average evolutionary 273 
rate of 0.9 AUs per year, somewhat lower than the rate reported over the 35-year 274 
period 1968 – 2003 of 1.2 AUs per year (15). Thus, the antigenic evolution of 275 
A/H2N2 virus was approximately two times slower than antigenic evolution of 276 
A/H3N2 during the first 12 years of circulation and three times slower than over the 277 
35-year period. 278 
To investigate if these differences in antigenic evolution were potentially due to 279 
increased evolutionary pressures to select antigenic escape mutants or as the 280 
consequence of an overall increased rate of nucleotide substitution in HA1, the 281 
nucleotide substitution rates were estimated using BEAST version 1.8.1 with a 282 
relaxed log-normal clock and the Bayesian skyride time-aware model. All available 283 
sequences in public databases were downloaded, which resulted in alignments of 98 284 
sequences for A/H2N2 virus HA1 and 103 sequences for H3N2 virus HA1 after 285 
curation. The mean rate of nucleotide substitution for A/H2N2 HA1 was determined 286 
to be 4.88×10-3 (highest posterior density or HPD 3.68×10-3 - 6.21×10-3) nucleotide 287 
substitutions per site per year. The nucleotide substitution rate of A/H3N2 virus HA1 288 
was determined to be 4.48×10−3 (HPD 3.57×10-3 - 5.49×10-3), comparable to 289 
previous results obtained for A/H3N2 HA1 at 5.15×10-3 (HPD 4.62×10-3 - 5.70×10-3) 290 
(36). This rate of A/H3N2 virus evolution was not statistically significantly different 291 
from the A/H2N2 virus rate (Bayes factors: H2>H3: 1.533, H3>H2: 0.651). 292 
 293 
Discussion 294 
Using a unique and comprehensive collection of human A/H2N2 viruses with low 295 
passage history and matching ferret post-infection sera spanning the time of 296 
circulation of A/H2N2 viruses in humans, the antigenic evolution of A/H2N2 viruses 297 
over time was analyzed. Phylogenetic analysis of HA sequences of human A/H2N2 298 
viruses resulted in the ladder-like structure of the phylogenetic tree (Figure 1) due to 299 
the gradual accumulation of mutations characteristic for human influenza A viruses 300 
(39, 40). All H2N2 virus isolates available at our institute were amplified by PCR and 301 
sequenced. They were confirmed to be representative of the major genetic diversity 302 
and were tested in HI assays for their reactivity to corresponding ferret antisera and 303 
to construct antigenic maps. The antigenic evolution of A/H2N2 viruses did not 304 
demonstrate obvious clustering of virus isolates in contrast to A/H3N2 viruses (22), 305 
but a rather gradual pattern of antigenic change over time. However, the number of 306 
strains included in the current analysis and the short time span of A/H2N2 virus 307 
circulation may simply be insufficient for clustering to be obvious. 308 
A single amino acid change from asparagine (N) to lysine (K) at position 139 in the 309 
HA molecule played a prominent role in determining the antigenic properties of 310 
A/H2N2 viruses. When introduced in either NL/M1/57 or NL/B1/68, this substitution 311 
had an antigenic effect of 2.9 antigenic units, describing roughly half of the observed 312 
antigenic diversity of A/H2N2 HA. No other single amino acid substitution was 313 
responsible for a greater antigenic effect than D128T in the context of NL/B1/68 314 
(Figure 3C and D). Both positions 128 and 139 are located close to the RBS in the 315 
HA protein, similar to the substitutions that were previously shown to be important for 316 
major antigenic change of other influenza A viruses and influenza B virus (22, 23, 317 
25). Additional individual substitutions at positions 126, 132, 154, 184 and 188, had 318 
only minor antigenic effect, but collectively with positions 139 and 128 explained the 319 
major antigenic changes observed in A/H2N2 viruses. Also, these changes were 320 
located in close proximity to the RBS (Figure 3). For the antigenic evolution of 321 
A/H3N2 virus, major antigenic change was caused by substitutions at only seven 322 
positions around the RBS, with relatively small effects of additional substitutions. For 323 
A/H2N2 virus, a single amino acid substitution also determined the antigenic 324 
phenotype of subsequent major drift variants, but the effect of additional substitutions 325 
was more substantial, potentially due to the different time scales at which the 326 
antigenic evolution was measured and the lack of clustering of strains in the A/H2N2 327 
map. 328 
Whereas A/H1N1pdm09 viruses remained remarkably antigenically stable since their 329 
introduction in humans (41, 42), A/H3N2 viruses displayed a more rapid 330 
accumulation of substitutions with major impact on antigenic evolution over time, 331 
possibly implying differential abilities of various HA subtypes to accommodate 332 
substitutions that affect antigenic properties (25, 43). The antigenic evolution of 333 
influenza B virus was also found to be relatively slow compared to A/H3N2 virus (22, 334 
37). Here, the antigenic evolution of A/H2N2 was found to be two times slower than 335 
the antigenic evolution of A/H3N2 virus during its first twelve years of circulation, and 336 
three times slower than during the period of A/H3N2 virus circulation from 1968 to 337 
2003, while their respective nucleotide substitution rates differed only slightly in the 338 
first 12 years of virus circulation in humans. Although the exact factors contributing to 339 
this difference in rates of antigenic evolution are not known, antibody mediated 340 
selection of escape mutants likely played an important role. Human sera obtained 341 
before 1957 from the elderly contained antibodies reacting to A/H2N2 virus, 342 
suggesting that the pandemic of 1889-1890 was also caused by an influenza A virus 343 
of the H2 subtype (44). However, this pre-existing immunity in the population 344 
apparently did not result in increased antibody mediated selection for A/H2N2 virus 345 
variants, similar to the lack of rapid natural selection of escape mutants for 346 
A/H1N1pdm09 virus. 347 
Combined, the genetic variability of A/H2N2 was comparable to other influenza A 348 
subtypes whereas the antigenic evolution was relatively slow, indicating that 349 
population immunity to A/H2N2 did not facilitate rapid antigenic evolution at the time 350 
of virus introduction. The genetic data indicate that the size of the susceptible 351 
population as well as virus turnover was likely similar to other influenza virus 352 
subtypes. We hypothesize that a combination of factors including the intrinsic 353 
capacity of the influenza virus HA to accumulate mutations responsible for antigenic 354 
evolution, preexisting immunity at the time of introduction, susceptible population 355 
size and prior circulation of a certain subtype leading to human adaptation have a 356 
combined effect on the HA to evolve antigenically. 357 
This study describes directional antigenic evolution of A/H2N2 viruses during 358 
circulation in humans and highlights the importance of amino acid sites in close 359 
proximity to the RBS for antigenic reactivity of A/H2N2 HA. Rates of antigenic 360 
evolution in A/H2N2 viruses were lower compared to A/H3N2 virus, possibly implying 361 
differences in the structural freedom of the HA molecules to evolve.  362 
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 370 
Figure 1: 371 
Maximum Likelihood phylogenetic tree based on HA1 amino acid sequences of 372 
human A/H2N2 viruses. Virus isolates used for antigenic characterization are 373 
highlighted in red.  374 
 375 
Figure 2: 376 
Antigenic map of human A/H2N2 influenza viruses as measured in HI assays 377 
with ferret postinfection antisera. Circles indicate the position of viruses, squares 378 
represent two ferret antisera each raised against A/Japan/305/57, A/Singapore/1/57, 379 
A/Netherlands/K1/63, A/England/1/66, A/Tokyo/3/67, A/Netherlands/B1/68. The 380 
underlying grid depicts the scale of antigenic difference between the viruses, with 381 
each square representing one antigenic unit or a 2-fold difference in HI titer. Years of 382 
isolation of the A/H2N2 virus isolates are indicated, ranging from red (1957) to blue 383 



















Figure 3: 386 
Summary of substitutions responsible for antigenic differences between 387 
NL/M1/57 and NL/B1/68 388 
Antigenic maps showing the antigenic change caused by individual amino acid 389 
substitutions introduced into NL/M1/57 (A) or NL/B1/68 (B) and combinations of 390 
mutations introduced into NL/M1/57 (C) or NL/B1/68 (D). Viruses are shown as 391 
circles of different color, with a diamond indicating the mutant virus with the largest 392 
antigenic distance to the corresponding wildtype strain. Sera are indicated as open 393 
squares. The underlying map of wildtype viruses from Figure 2 is shown in grey and 394 
its positioning is kept constant. The arrows indicate the antigenic distance of a 395 
double mutant that spans a long distance between the earliest and latest isolates of 396 
A/H2N2. Structure of an HA trimer (E) with individual monomers in shades of grey, 397 
the RBS in yellow and mutations near the RBS with a measurable effect on 398 
antigenicity in orange (E). The two mutations with the biggest combined effect in (C) 399 
were colored in red (T128D, N139K).  400 
 401 
Figure 4: 402 
Rates of genetic and antigenic evolution of A/H2N2 and A/H3N2 virus during 12 403 
years of circulation in humans. Genetic (A) and antigenic (B) distances of the 404 
A/H2N2 (red squares) and A/H3N2 (blue circles) viruses from the first human virus 405 
isolates in 1957 (A/Netherlands/M1/1957) and 1968 (A/Bilthoven/16190/1968). Rates 406 


















































































  JP/305/57 SP/1/57 NL/K1/63 EN/1/66 TY/3/67 NL/B1/68 
A/NETHERLANDS/M1/57 [NL/M1/57] 2560 1600 1280 320 40 160 
A/NETHERLANDS/M2/57 [NL/M2/57] 960 1600 960 240 40 80 
A/SINGAPORE/1/57 [SP/1/57] 1600 1920 1280 160 35 60 
A/NETHERLANDS/M1/58 [NL/M1/58] 960 960 960 160 30 60 
A/NETHERLANDS/N1/59 [NL/N1/59] 1920 1920 1920 800 240 240 
A/NETHERLANDS/H1/60 [NL/H1/60] 1920 1600 2560 480 120 200 
A/NETHERLANDS/67/63 [NL/67/63] 560 1280 4480 560 240 800 
A/NETHERLANDS/K1/63 [NL/K1/63] 1600 1120 5760 960 200 800
A/ENGLAND/12/64 [EN/12/64] 60 240 2240 2880 320 1120 
A/SYDNEY/2/64 [SY/2/64] 480 800 480 200 60 160 
A/TAIWAN/1/64 [TA/1/64] 80 320 1120 1920 320 1120 
A/MOSCOW/56/65 [MW/56/65] 560 240 2560 480 240 1280 
A/ENGLAND/1/66 [EN/1/66] 640 320 3840 6400 320 2240 
A/ENGLAND/10/67 [EN/10/67] 1120 320 2560 800 240 1120 
A/TOKYO/3/67 [TY/3/63] 80 80 160 320 960 320 
A/NETHERLANDS/61/68 [NL/61/68] 320 160 1120 2240 160 800 
A/NETHERLANDS/B1/68 [NL/B1/68] 20 80 960 960 320 2880
A/NETHERLANDS/B2/68 [NL/B2/68] 50 60 320 640 640 640 
 408 
Table 1: Hemagglutination inhibition titers for wildtype viruses towards 409 
A/H2N2 postinfection ferret antisera  410 
One serum per isolate was selected to represent the two individual ferret sera since 411 
variation in HI titers between repeat sera was negligible. Viruses emphasized in 412 
Figure 3 are in bold and homologous HI titers are underlined.  413 
 JP/305/57 SP/1/57 NL/K1/63 EN/1/66 TY/3/67 NL/B1/68 
NL/M1/57_T126E 1600 1440 640 320 80 560 
NL/M1/57_T128D 1600 960 640 280 80 640
NL/M1/57_R132K 2240 1280 640 800 80 320 
NL/M1/57_N139K 160 1120 640 1920 80 640 
NL/M1/57_S154P 1920 1280 1280 560 360 280 
NL/M1/57_T184A 1600 1920 1120 320 20 160 
NL/M1/57_T188A 1280 1600 1920 480 20 160 
NL/B1/68_E126T 40 80 640 960 160 1280 
NL/B1/68_D128T 1120 240 1440 2240 160 2240 
NL/B1/68_K139N 400 160 640 320 320 2240 
NL/B1/68_P154S 20 160 640 800 320 3200
NL/B1/68_A184T 40 120 480 640 160 2560 
NL/B1/68_A188T 20 100 160 320 240 1920 
NL/M1/57_T126EN139K 560 640 640 1920 160 1920 
NL/M1/57_T128DN139K 80 640 640 1120 160 2240 
NL/M1/57_T126ET128DN139K 100 640 320 800 140 2880 
NL/M1/57_T126ET128DR132KN139K 160 560 280 800 160 1920 
NL/M1/57_T126ET128DN139KS154PT184AT188A 80 320 960 800 160 3200 
NL/M1/57_T126ET128DR132KN139KS154PT184A
T188A 80 320 640 800 160 2560 
NL/B1/68_E126TK139N 160 320 480 320 160 640 
NL/B1/68_D128TK139N 320 480 1280 320 160 640 
NL/B1/68_E126TD128T 80 80 960 640 80 640
NL/B1/68_E126TD128TK139N 960 480 2240 640 160 640 
NL/B1/68_E126TD128TK139NK132R 640 400 2240 320 60 320 
NL/B1/68_E126TD128TK139NP154SA184TA188T 960 560 480 280 160 100
NL/B1/68_E126TD128TR132KK139NP154SA184T
A188T 640 480 640 60 50 40 
 414 
Table 2: Hemagglutination inhibition titers for mutant viruses towards A/H2N2 415 
postinfection ferret antisera   416 
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